BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol. 1999;13:82-90. [PMID: 9892014 DOI: 10.1210/mend.13.1.0220] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhou G, Gingras MC, Liu SH, Li D, Li Z, Catania RL, Stehling KM, Li M, Paganelli G, Gibbs RA, Demayo FJ, Fisher WE, Brunicardi FC. The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function. World J Surg 2011;35:1715-24. [PMID: 21249361 DOI: 10.1007/s00268-010-0939-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
2 Komatsuzaki K, Terashita K, Kinane TB, Nishimoto I. Somatostatin type V receptor activates c-Jun N-terminal kinases via Galpha(12) family G proteins. Biochem Biophys Res Commun. 2001;289:1211-1217. [PMID: 11741322 DOI: 10.1006/bbrc.2001.6085] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
3 Condon LT, Stafford ND, Bedford KJ, Macdonald AW, Atkin SL. The expression of somatostatin receptors 3, 4 and 5 in laryngeal pathology. Eur Arch Otorhinolaryngol 2008;265:63-7. [DOI: 10.1007/s00405-007-0539-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Goddard I, Bauer S, Gougeon A, Lopez F, Giannetti N, Susini C, Benahmed M, Krantic S. Somatostatin inhibits stem cell factor messenger RNA expression by Sertoli cells and stem cell factor-induced DNA synthesis in isolated seminiferous tubules. Biol Reprod 2001;65:1732-42. [PMID: 11717135 DOI: 10.1095/biolreprod65.6.1732] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
5 Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol. 2003;9:1144-1155. [PMID: 12800214 DOI: 10.3748/wjg.v9.i6.1144] [Cited by in CrossRef: 131] [Cited by in F6Publishing: 107] [Article Influence: 7.3] [Reference Citation Analysis]
6 Cambiaghi V, Vitali E, Morone D, Peverelli E, Spada A, Mantovani G, Lania AG. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine 2017;56:146-57. [DOI: 10.1007/s12020-016-1026-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
7 Talme T, Ivanoff J, Hägglund M, Van Neerven RJ, Ivanoff A, Sundqvist KG. Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3. Clin Exp Immunol 2001;125:71-9. [PMID: 11472428 DOI: 10.1046/j.1365-2249.2001.01577.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
8 War SA, Kim B, Kumar U. Human somatostatin receptor-3 distinctively induces apoptosis in MCF-7 and cell cycle arrest in MDA-MB-231 breast cancer cells. Molecular and Cellular Endocrinology 2015;413:129-44. [DOI: 10.1016/j.mce.2015.06.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
9 Stafford ND, Condon LT, Rogers MJ, Helboe L, Crooks DA, Atkin SL. The immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas. J Clin Pathol 2004;57:168-71. [PMID: 14747443 DOI: 10.1136/jcp.2003.007260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
10 Aoki T, Motoi F, Sakata N, Naitoh T, Katayose Y, Egawa S, Miyazaki J, Unno M. Somatostatin analog inhibits the growth of insulinoma cells by p27-mediated G1 cell cycle arrest. Pancreas 2014;43:720-9. [PMID: 24694834 DOI: 10.1097/MPA.0000000000000128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
11 Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20:255-264. [PMID: 12721505 DOI: 10.1385/endo:20:3:255] [Cited by in Crossref: 91] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
12 Peverelli E, Lania AG, Mantovani G, Beck-Peccoz P, Spada A. Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop. Endocrinology 2009;150:3169-76. [PMID: 19342453 DOI: 10.1210/en.2008-1785] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
13 Yusta B, Boushey RP, Drucker DJ. The Glucagon-like Peptide-2 Receptor Mediates Direct Inhibition of Cellular Apoptosis via a cAMP-dependent Protein Kinase-independent Pathway. Journal of Biological Chemistry 2000;275:35345-52. [DOI: 10.1074/jbc.m005510200] [Cited by in Crossref: 77] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
14 Steták A, Csermely P, Ullrich A, Kéri G. Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta. Biochem Biophys Res Commun 2001;288:564-72. [PMID: 11676480 DOI: 10.1006/bbrc.2001.5811] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
15 Filopanti M, Ballarè E, Lania AG, Bondioni S, Verga U, Locatelli M, Zavanone LM, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest 2004;27:937-42. [PMID: 15762041 DOI: 10.1007/BF03347536] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hernández B, Carelli C, Coïc YM, De Coninck J, Ghomi M. Vibrational analysis of amino acids and short peptides in aqueous media. V. The effect of the disulfide bridge on the structural features of the peptide hormone somatostatin-14. J Phys Chem B 2009;113:12796-803. [PMID: 19708669 DOI: 10.1021/jp904737v] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
17 Alexandraki KI, Grossman AB. Pituitary-targeted medical therapy of Cushing's disease. Expert Opin Investig Drugs 2008;17:669-77. [PMID: 18447593 DOI: 10.1517/13543784.17.5.669] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
18 Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20:255-264. [PMID: 12721505 DOI: 10.1385/ENDO: 20: 3: 255] [Reference Citation Analysis]
19 Hukovic N, Rocheville M, Kumar U, Sasi R, Khare S, Patel YC. Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. J Biol Chem. 1999;274:24550-24558. [PMID: 10455118 DOI: 10.1074/jbc.274.35.24550] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.6] [Reference Citation Analysis]
20 Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 2001;35:1-23. [PMID: 11346306 DOI: 10.1054/npep.2001.0848] [Cited by in Crossref: 169] [Cited by in F6Publishing: 146] [Article Influence: 8.5] [Reference Citation Analysis]
21 Charland S, Boucher MJ, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology. 2001;142:121-128. [PMID: 11145574 DOI: 10.1210/endo.142.1.7908] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
22 Dong H, Wei Y, Xie C, Zhu X, Sun C, Fu Q, Pan L, Wu M, Guo Y, Sun J, Shen H, Ye J. Structural and functional analysis of two novel somatostatin receptors identified from topmouth culter (Erythroculter ilishaeformis). Comp Biochem Physiol C Toxicol Pharmacol 2018;210:18-29. [PMID: 29698686 DOI: 10.1016/j.cbpc.2018.04.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Wood WM, Sarapura VD, Dowding JM, Woodmansee WW, Haakinson DJ, Gordon DF, Ridgway EC. Early Gene Expression Changes Preceding Thyroid Hormone-Induced Involution of a Thyrotrope Tumor. Endocrinology 2002;143:347-59. [DOI: 10.1210/endo.143.2.8636] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
24 Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal 2001;13:777-85. [PMID: 11583913 DOI: 10.1016/s0898-6568(01)00192-9] [Cited by in Crossref: 203] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
25 Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003;1616:1-84. [PMID: 14507421 DOI: 10.1016/s0005-2736(03)00235-9] [Cited by in Crossref: 230] [Cited by in F6Publishing: 76] [Article Influence: 12.8] [Reference Citation Analysis]
26 Ciganoka D, Balcere I, Kapa I, Peculis R, Valtere A, Nikitina-Zake L, Lase I, Schiöth HB, Pirags V, Klovins J. Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. Eur J Endocrinol 2011;165:517-25. [PMID: 21810856 DOI: 10.1530/EJE-11-0416] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
27 Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-198. [PMID: 10433861 DOI: 10.1006/frne.1999.0183] [Cited by in Crossref: 1123] [Cited by in F6Publishing: 884] [Article Influence: 51.0] [Reference Citation Analysis]
28 Pan Q, Li DG, Lu HM, Lu LY, Wang YQ, Xu QF. Antiproliferative and proapoptotic effects of somatostatin on activated hepatic stellate cells. World J Gastroenterol 2004;10:1015-8. [PMID: 15052685 DOI: 10.3748/wjg.v10.i7.1015] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
29 Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2011;1813:1172-89. [DOI: 10.1016/j.bbamcr.2011.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
30 Lin C, Varma MG, Joubel A, Madabushi S, Lichtarge O, Barber DL. Conserved Motifs in Somatostatin, D2-dopamine, and α2B-Adrenergic Receptors for Inhibiting the Na-H Exchanger, NHE1. Journal of Biological Chemistry 2003;278:15128-35. [DOI: 10.1074/jbc.m212315200] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
31 Kumar U. Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J Comp Neurol 2007;504:185-205. [PMID: 17626271 DOI: 10.1002/cne.21444] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
32 Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000;275:7862-7869. [PMID: 10713101 DOI: 10.1074/jbc.275.11.7862] [Cited by in Crossref: 367] [Cited by in F6Publishing: 338] [Article Influence: 17.5] [Reference Citation Analysis]
33 Fisher WE, Wu Y, Amaya F, Berger DH. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J Surg Res. 2002;105:58-64. [PMID: 12069503 DOI: 10.1006/jsre.2002.6450] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
34 Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511. [PMID: 15180952 DOI: 10.1210/er.2003-0014] [Cited by in Crossref: 401] [Cited by in F6Publishing: 275] [Article Influence: 23.6] [Reference Citation Analysis]
35 War SA, Somvanshi RK, Kumar U. Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim Biophys Acta 2011;1813:390-402. [PMID: 21194548 DOI: 10.1016/j.bbamcr.2010.12.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
36 Hofland LJ, Lamberts SWJ. The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance. Endocrine Reviews 2003;24:28-47. [DOI: 10.1210/er.2000-0001] [Cited by in Crossref: 317] [Cited by in F6Publishing: 252] [Article Influence: 63.4] [Reference Citation Analysis]
37 Filopanti M, Ronchi C, Ballarè E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005;90:4824-8. [PMID: 15914528 DOI: 10.1210/jc.2005-0132] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
38 Nakayama Y, Wada R, Yajima N, Hakamada K, Yagihashi S. Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors. Pancreas 2010;39:1147-54. [PMID: 20717067 DOI: 10.1097/MPA.0b013e3181e78120] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
39 Barbieri F, Pattarozzi A, Gatti M, Porcile C, Bajetto A, Ferrari A, Culler MD, Florio T. Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology 2008;149:4736-46. [PMID: 18566118 DOI: 10.1210/en.2007-1762] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
40 Ballian N, Brunicardi FC, Wang X. Somatostatin and its Receptors in the Development of the Endocrine Pancreas. Pancreas 2006;33:1-12. [DOI: 10.1097/01.mpa.0000226894.16817.e8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
41 Arnold R, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother. 2002;3:643-656. [PMID: 12472080 DOI: 10.1517/14656566.3.6.643] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
42 Radford IR, Lobachevsky PN. An enteroendocrine cell-based model for a quiescent intestinal stem cell niche. Cell Prolif 2006;39:403-14. [PMID: 16987141 DOI: 10.1111/j.1365-2184.2006.00396.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
43 Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005;92:175-86. [DOI: 10.1007/s10549-005-2414-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
44 Wang XP, Norman MA, Brunicardi FC. Somatostatin receptors and autoimmune-mediated diabetes. Diabetes Metab Res Rev 2005;21:15-30. [PMID: 15624122 DOI: 10.1002/dmrr.531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
45 Horuk R, Salamon H, Lu H. The biology and physiology of somatostatin receptors. Expert Opinion on Therapeutic Targets 2005;5:613-23. [DOI: 10.1517/14728222.5.5.613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121-131. [PMID: 15153426 DOI: 10.1196/annals.1294.012] [Cited by in Crossref: 109] [Cited by in F6Publishing: 84] [Article Influence: 6.4] [Reference Citation Analysis]
47 Riaz H, Liang A, Khan MK, Dong P, Han L, Shahzad M, Chong Z, Ahmad S, Hua G, Yang L. Somatostatin and its receptors: functional regulation in the development of mice Sertoli cells. J Steroid Biochem Mol Biol 2013;138:257-66. [PMID: 23831358 DOI: 10.1016/j.jsbmb.2013.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience 2018;7. [PMID: 29757368 DOI: 10.1093/gigascience/giy050] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
49 Dolan JT, Miltenburg DM, Granchi TS, Miller CC, Brunicardi FC. Treatment of Metastatic Breast Cancer With Somatostatin Analogues?A Meta-Analysis. Ann Surg Oncol 2001;8:227-33. [DOI: 10.1007/s10434-001-0227-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]